Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

Specimen Handling 4Gemcitabine 3Doxorubicin 3liposomal doxorubicin 2Trabectedin 2Magnetic Resonance Spectroscopy 2Dacarbazine 2Biopsy 2toripalimab 1regorafenib 1peposertib 1cemiplimab 1anlotinib 1abemaciclib 1X-Rays 1Tretinoin 1Tissue Banks 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosuvastatin Calcium 1Radiotherapy 1Quality of Life 1Nivolumab 1Neoadjuvant Therapy 1Midazolam 1Injections 1Immunoglobulin G 1Ifosfamide 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leiomyosarcoma × Injections × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡